Cost-effectiveness watchdog for England and Wales the National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabazitaxel, which is marketed as Jevtana by French pharma major Sanofi (Euronext: SAN), for some prostate cancer patients.
This is a change from the appraisal committee’s draft guidance (The Pharma Letter May 11, 2012).The committee previously did not recommend cabazitaxel because of concerns about its cost-effectiveness compared with standard treatments (such as abiraterone, enzalutamide or radium-223 dichloride).
After the medicine was turned down, Sanofi increased the discount and confirmed that it can supply cabazitaxel in intravenous bags instead of vials, reducing waste. Therefore, the committee concluded that cabazitaxel is a cost-effective treatment option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze